Last updated: April 25, 2026
What supply the active ingredients for ampicillin and sulbactam?
Ampicillin and sulbactam are sourced through a mix of large global API manufacturers and India/China-based specialty antibiotic API producers. Supply is typically structured as either:
- Single APIs (ampicillin API, sulbactam API) supplied separately
- Fixed-dose intermediates / combination-ready API packages used by formulators for finished dosage manufacture
Common supplier network (API and key intermediates)
The market for beta-lactam antibiotics is concentrated among certified producers with CEPs (where applicable) and established documentation packages for regulatory filings.
| Supplier type |
Where supply comes from |
Typical deliverable |
| API manufacturer |
China, India, Europe |
Ampicillin API, sulbactam API |
| Intermediates producer |
China/India supply chains |
Beta-lactam intermediate steps used for final API |
| CMDO/CDMO |
Multi-country formulation sites |
Finished sterile injectables and solid oral products |
| Local distributors |
Country-specific networks |
Contract distribution of branded and generic products |
Which finished-dose manufacturers supply ampicillin and sulbactam injections?
Finished-dose injectable products are often made by global sterile injectables manufacturers and regional generics houses under CDMO or in-house production models. Typical presentations in the market are:
- Ampicillin/sulbactam 1.5 g (commonly 1 g ampicillin + 0.5 g sulbactam)
- Ampicillin/sulbactam 3 g (commonly 2 g ampicillin + 1 g sulbactam)
Finished product supply patterns
- Tenders and hospital procurement commonly source through local registered generic manufacturers.
- Global origin is frequently China or India for API, with the final sterile fill-finish done regionally for speed to registration and logistics.
How do suppliers position documentation for regulatory approval?
For antibiotics, buyers usually require a complete regulatory dossier pack:
- CoA and batch release documentation
- Stability data matched to dosage form
- Quality agreements defining impurities, residual solvents, and beta-lactam degradation controls
From a procurement perspective, supplier readiness depends on whether they can support:
- DMF/ASMF coverage (for API filings)
- CEP availability (for some markets and product configurations)
- GMP compliance at manufacturing site level
What selection criteria decide supplier qualification in procurement?
Procurement for ampicillin/sulbactam typically evaluates suppliers on:
| Criterion |
What procurement checks |
| GMP status |
Current GMP compliance for API and/or sterile fill-finish |
| Beta-lactam quality controls |
Impurity profile, residual solvents, water activity control for solids, degradation control for solutions |
| Batch consistency |
Multi-batch CoA alignment for assay and related substances |
| Documentation |
DMF/ASMF completeness, stability package, change control history |
| Supply reliability |
Minimum order quantities, lead times, and backup manufacturing sites |
What contract manufacturers (CMOs/CDMOs) typically handle ampicillin/sulbactam?
CMOs/CDMOs that serve antibiotics generally cover:
- Sterile manufacturing (aseptic or terminal sterilization depending on formulation)
- Lyophilized or powder-for-reconstitution production for injectables
- Solid oral formulations (less common for this specific combination in many markets)
Procurement for this combination frequently targets CMDO capacity for:
- 1.5 g and 3 g vials
- Powder bulk fill and aseptic finishing
- Packaging into hospital-ready kits (where required by tenders)
What are the common API sourcing risks for ampicillin/sulbactam?
Supply continuity often depends on beta-lactam intermediate availability, which can tighten when plants consolidate or when regulators increase inspection intensity.
Key risk categories:
- Intermediate shortages in upstream beta-lactam chemistry
- Inspection outcomes affecting batch release and approval status
- Market volatility tied to antibiotic demand cycles and local tender dynamics
What to request in RFQ to lock supplier fit quickly
To avoid rework, buyers typically request a dossier-aligned RFQ package:
- API grades supported (sterile injectable grade vs general API grade, as relevant)
- Impurity specifications and testing methods
- DMF/ASMF status and reference documents
- Batch CoA from at least two recent lots
- Lead time and MOQ, plus secondary sourcing options
Key Takeaways
- Ampicillin/sulbactam supply is dominated by API producers in China and India plus sterile injectable manufacturers that do regional fill-finish.
- Procurement qualification hinges on GMP coverage, beta-lactam impurity controls, and complete regulatory documentation (DMF/ASMF/CEP where relevant).
- For tenders and hospital supply, lead time and 1.5 g / 3 g vial capacity are often decisive.
- Supplier selection should be driven by batch consistency, documentation readiness, and backup production capacity.
FAQs
-
Do suppliers usually provide ampicillin and sulbactam as separate APIs or as a combination API?
Both models exist; most procurement buys separately for flexibility, while some supply chains support combination-ready packaging.
-
What dosage strengths dominate hospital procurement for ampicillin/sulbactam?
Common strengths are 1.5 g and 3 g presentations for injection (typical vial compositions are 1 g+0.5 g and 2 g+1 g).
-
What documents matter most when qualifying an API supplier for beta-lactams?
GMP evidence, impurity specification set, recent CoAs, stability package, and DMF/ASMF or CEP documentation.
-
What manufacturing step is usually the bottleneck for injectable supply?
Sterile fill-finish capacity and the availability of conforming API intermediates for consistent beta-lactam quality.
-
How do buyers reduce supply interruption risk for antibiotics?
Dual sourcing, qualification of backup plants, and contractual controls on batch release documentation and change notifications.
References
No sources were provided in the prompt, and none were cited.
